Portal de Periódicos da CAPES

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

2022; Lippincott Williams & Wilkins; Volume: 40; Issue: 22 Linguagem: Inglês

10.1200/jco.21.01829

1527-7755

Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant P. Chawla, Javier Martín‐Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoîne Italiano, Xavier García del Muro, Melissa Burgess, Sophie Piperno‐Neumann, Christopher W. Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott H. Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean‐Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari A. Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Gröschel, Helen Hatcher, Florence Duffaud, Antonio Casado, Roberto Díaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian F. Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina S. Götze, F Mazzeo, Alexander Yakobson, Aviad Zick, Alexander T.J. Lee, Anna Estival, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben‐Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Steven Attia,

Cardiac tumors and thrombi

Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents.